Moderna biotech company has been licensed to circulate Covid-19-resistant vaccine and at the same time reached an agreement with the US government to supply 200 million doses by mid-2021.
|After thawing, Moderna vaccine can be stored at dedicated refrigerator temperatures. Photo: Shutterstock|
The good news about the second Covid-19 vaccine comes to Americans as the country is still struggling to deal with the epidemic, with the number of Covid-19 infections rising after Thanksgiving and especially the number of deaths from the virus. in the US to date has exceeded 307,000.
Moderna’s millions of vaccine doses are expected to supplement the current US vaccine distribution campaign. According to the plan, health workers will be vaccinated against Covid-19 this week, followed by the elderly in long-term nursing facilities. Ntomorrow 20/12, nThe Center for Disease Control and Prevention’s team of experts plans to propose additional priority groups to be vaccinated.
The Covid-19-resistant vaccine produced by Moderna was approved for emergency use by the US Food and Drug Administration (FDA) on December 18, a day after the agency’s external panel of experts “nodded. first “and a week after the US Food and Drug Administration issued an emergency license for the first US Covid-19 resistant vaccine developed by the pharmaceutical company Pfizer and its German partner BioNTech.
The vaccine, developed by Pfizer and BioNTech, is also based on similar technologies, delivered to thousands of health workers in the US-wide vaccine distribution over the past week. It is expected that people aged 18 and over in the US will start receiving Moderna’s vaccine in the coming days.
“With the licensing of these two vaccines, the US Food and Drug Administration has taken an important step in the fight against a pandemic that causes large numbers of Americans to be hospitalized and killed every day,” said Stephen M. Hahn , Said the US Food and Drug Administration.
What’s more, Moderna’s vaccine is expected to better reach difficult-to-reach areas, such as hospitals in rural areas. The vaccines made by Moderna still need to be stored and transported frozen, but do not require as high a refrigeration temperature as the Pfizer vaccine.
Advantages of Moderna’s vaccine is sAfter thawing, the vaccine can be stored at dedicated refrigerator temperatures. The Moderna vaccine is injected into two different doses, 28 days apart.
The rapid rate of vaccine development in less than a year since the arrival of the Covid-19 pandemic in the United States has been a staggering scientific success, despite certain public hesitation.
“I hope all Americans will protect themselves by getting vaccinated. That’s how America will begin to recover and move forward,” said Anthony Fauci, America’s leading Infectious Diseases scientist. .
The US Food and Drug Administration’s emergency licensing decision marks the world’s first licensing of a vaccine line manufactured by Moderna, and also confirms the technology to synthesize RNA genes with effective resistance. virus is close to 95% without serious concern about safety.
The Covid-19-resistant vaccine was developed by Moderna in cooperation with the US National Institutes of Health. The vaccine is estimated to cause relatively minor side effects such as pain around the injection site and swelling.
Moderna says it has worked with the US government to prepare to distribute 5.9 million shots of vaccine by the end of this week. In addition, the company also plans to apply for a full US license by 2021.
With the licensing of the two vaccines, the United States expects to complete 40 million doses of vaccination by the end of 2020, which is enough to vaccinate 20 million people, as both vaccines require adequate vaccinations. two noses.
“Bright days are still ahead,” said US President-elect Joe Biden, who plans to get a Covid-19-resistant vaccine early next week.
And current US President Donald Trump praised the move to license the use of Moderna vaccines on his Twitter personal page. “Congratulations, Moderna vaccine is now available,” Trump wrote.
Moderna says it will deliver about 20 million doses to the US government by 2020 and plans to deliver 100 to 125 million doses globally in the first quarter of 2021, of which 85-100 million doses are for Americans. .
Moderna also reached an agreement with the US government to provide a total of 200 million doses of vaccine by the end of June 2021. Meanwhile, other Covid-19-resistant vaccines are still in the testing process, including the one-shot vaccine developed by Johnson & Johnson, the two-shot vaccine coordinated by AstraZeneca Pharmaceutical Company and Oxford University. research.